AR105171A1 - ANTIBODIES AGAINST CD40 WITH IMPROVED AGONIST ACTIVITY - Google Patents

ANTIBODIES AGAINST CD40 WITH IMPROVED AGONIST ACTIVITY

Info

Publication number
AR105171A1
AR105171A1 ARP160101948A ARP160101948A AR105171A1 AR 105171 A1 AR105171 A1 AR 105171A1 AR P160101948 A ARP160101948 A AR P160101948A AR P160101948 A ARP160101948 A AR P160101948A AR 105171 A1 AR105171 A1 AR 105171A1
Authority
AR
Argentina
Prior art keywords
antibodies against
agonist activity
antibodies
improved agonist
improved
Prior art date
Application number
ARP160101948A
Other languages
Spanish (es)
Inventor
L Stevens Brenda
L Okada Shannon
P Yamniuk Aaron
Devaux Brigitte
C Barnhart Bryan
Dahan Rony
V Ravetch Jeffrey
Original Assignee
Univ Rockefeller
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller, Bristol Myers Squibb Co filed Critical Univ Rockefeller
Publication of AR105171A1 publication Critical patent/AR105171A1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Anticuerpos agonistas, o porciones de fijación al antígeno de estos, que se fijan a CD40 humana. Dichos anticuerpos comprenden opcionalmente regiones Fc con especificidad mejorada para FcgRIIb. También métodos para el tratamiento del cáncer o la infección crónica mediante la administración de los anticuerpos de la presente a un sujeto que lo necesita.Agonist antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with improved specificity for FcgRIIb. Also methods for the treatment of cancer or chronic infection by administering the present antibodies to a subject in need.

ARP160101948A 2015-06-29 2016-06-28 ANTIBODIES AGAINST CD40 WITH IMPROVED AGONIST ACTIVITY AR105171A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562186076P 2015-06-29 2015-06-29

Publications (1)

Publication Number Publication Date
AR105171A1 true AR105171A1 (en) 2017-09-13

Family

ID=59981278

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160101948A AR105171A1 (en) 2015-06-29 2016-06-28 ANTIBODIES AGAINST CD40 WITH IMPROVED AGONIST ACTIVITY

Country Status (1)

Country Link
AR (1) AR105171A1 (en)

Similar Documents

Publication Publication Date Title
UY36757A (en) MONOCLONAL ANTIBODIES AGAINST CD40 WITH IMPROVED AGONIST ACTIVITY
CO2018000809A2 (en) Antibodies for cd40
EA201890131A1 (en) IMMUNOMODULATION AND TREATMENT OF SOLID TUMORS BY ANTIBODIES THAT SPECIFICALLY CONNECT CD38
MX2018010672A (en) Antibodies to cd40 with enhanced agonist activity.
PE20171556A1 (en) CD123 BINDING AGENTS AND USES OF THEM
EA201990293A1 (en) MULTI-SPECIFIC ANTIBODIES AGAINST CD40 AND CD137
BR112018014016A2 (en) combination of an ox40 agonist and a 4-1bb monoclonal antibody agonist for cancer treatment
EA201791093A1 (en) ANTIBODIES TO CD47, METHODS AND USE
MY192226A (en) Anti-tigit antigen-binding proteins and methods of use thereof
EA201991214A1 (en) ANTIBODIES AGAINST PD-1 AND THEIR COMPOSITION
MX2016002826A (en) Anti-b7-h1 antibodies for treating tumors.
ES2765949T8 (en) Therapy involving antibodies to claudin 18.2 for cancer treatment
BR112015021115A2 (en) apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EA201491330A1 (en) THERAPEUTICALLY ACTIVE CONNECTIONS AND METHODS OF THEIR USE
EA201690206A1 (en) THERAPEUTICALLY ACTIVE COMPOUNDS AND METHODS OF THEIR APPLICATION
EA201691541A1 (en) NEW ANTI-BAFF ANTIBODIES
CL2017000050A1 (en) Combination Therapy for Cancer
UY35493A (en) METHODS FOR THE TREATMENT OF IMPERFECT OSTEOGENESIS
BR112016002401A2 (en) methods to reduce asthma exacerbation rates using benralizumab
EA201890747A1 (en) METHODS OF TREATING INFLAMMATORY DISEASES
EA201691020A1 (en) METHODS OF TREATMENT AND PREVENTION OF CALLED ALLOGEN ANTIBODIES OF CHRONIC DISEASE "TRANSPLANTAT AGAINST THE OWNER"
EA201791875A1 (en) COMBINED COMPOSITION OF THESOPHENZINE AND BETA BLOCKER
TR201910413T4 (en) Methods for improving asthma symptoms using benralizumab.
BR112018013847A2 (en) methods for administering angiotensin ii
EA201791819A1 (en) COMBINED THERAPY WITH ANTIBODY CONJUGATE AGAINST CD19 WITH MEDICINE AND VINCRISTINE

Legal Events

Date Code Title Description
FB Suspension of granting procedure